

Press Release

Astellas Reaches Settlement Agreement with Lupin in Myrbetriq[®] Patent Litigation

TOKYO, February 10, 2026 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that it has reached an agreement with Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively “Lupin”) to settle pending U.S. patent litigation regarding Astellas’ Myrbetriq[®] (generic name: Mirabegron).

This settlement concludes all litigation between Astellas and Lupin relating to Myrbetriq[®] and mirabegron. The terms of the settlement are confidential, and litigations involving Myrbetriq[®] with other companies remain ongoing.

Astellas is reviewing potential financial impacts of this matter for the fiscal year ending March 31, 2026.

About Astellas

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas’ intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries:

Astellas Pharma Inc.
Corporate Communications
+81-3-3244-3201